Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)
P Spagnolo, O Distler, CJ Ryerson… - Annals of the …, 2021 - ard.bmj.com
Interstitial lung diseases (ILDs), which can arise from a broad spectrum of distinct
aetiologies, can manifest as a pulmonary complication of an underlying autoimmune and …
aetiologies, can manifest as a pulmonary complication of an underlying autoimmune and …
COVID-19: the potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection
In December 2019, a novel coronavirus, SARS-CoV-2, appeared, causing a wide range of
symptoms, mainly respiratory infection. In March 2020, the World Health Organization …
symptoms, mainly respiratory infection. In March 2020, the World Health Organization …
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial
Background At present, no approved pharmacotherapies are available for unclassifiable
interstitial lung disease (ILD), which is characterised by progressive fibrosis of the lung. We …
interstitial lung disease (ILD), which is characterised by progressive fibrosis of the lung. We …
BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis
FE Herrmann, C Hesslinger, L Wollin… - Frontiers in …, 2022 - frontiersin.org
The anti-inflammatory and immunomodulatory abilities of oral selective phosphodiesterase
4 (PDE4) inhibitors enabled the approval of roflumilast and apremilast for use in chronic …
4 (PDE4) inhibitors enabled the approval of roflumilast and apremilast for use in chronic …
Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
BF Collins, G Raghu - European Respiratory Review, 2019 - Eur Respiratory Soc
Two antifibrotic medications (nintedanib and pirfenidone) were recommended
(conditionally) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) in the …
(conditionally) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) in the …
[HTML][HTML] Acute exacerbations of progressive-fibrosing interstitial lung diseases
M Kolb, B Bondue, A Pesci, Y Miyazaki… - European …, 2018 - Eur Respiratory Soc
Acute exacerbation of interstitial lung disease (ILD) is associated with a poor prognosis and
high mortality. Numerous studies have documented acute exacerbation in idiopathic …
high mortality. Numerous studies have documented acute exacerbation in idiopathic …
A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticity
N Roehlen, A Saviano, H El Saghire… - Science translational …, 2022 - science.org
Tissue fibrosis is a key driver of end-stage organ failure and cancer, overall accounting for
up to 45% of deaths in developed countries. There is a large unmet medical need for …
up to 45% of deaths in developed countries. There is a large unmet medical need for …
Nintedanib in progressive pulmonary fibrosis: a systematic review and meta-analysis
M Ghazipura, MJ Mammen, DD Herman… - Annals of the …, 2022 - atsjournals.org
Background: The American Thoracic Society, European Respiratory Society, Japanese
Respiratory Society, and Asociación Latinoamericana del Tórax convened to update clinical …
Respiratory Society, and Asociación Latinoamericana del Tórax convened to update clinical …
Pirfenidone in progressive pulmonary fibrosis: a systematic review and meta-analysis
Background: The American Thoracic Society, European Respiratory Society, Japanese
Respiratory Society, and Asociación Latinoamericana del Tórax convened to update clinical …
Respiratory Society, and Asociación Latinoamericana del Tórax convened to update clinical …
Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases
V Cottin - European Respiratory Review, 2019 - Eur Respiratory Soc
Interstitial lung disease (ILD) refers to a large and heterogeneous group of parenchymal
lung disorders [1], some related to other diseases such as connective tissue diseases …
lung disorders [1], some related to other diseases such as connective tissue diseases …